1. Sulphonylurea derivatives are commonly used in the treatment of non-insulin-dependent diabetes mellitus. It is, however, unclear whether the hypoglycaemic effect of sulphonylurea derivatives is additive to the effect of glucose, or whether sulphonylurea derivatives act by increasing B-cell glucose sensitivity.
INTRODUCTION
Sulphonylurea (SU) derivatives have often been advocated in the management of non-insulin-dependent diabetes mellitus (NIDDM). Although there is a continuing debate about their mode of action during chronic use in patients with NIDDM, notably whether the hypoglycaemic effect of the SU derivatives is mainly due to an insulinogenic effect or to an extrapancreatic effect, i.e. a stimulation of insulin action, there is little doubt about the capacity of these compounds to stimulate insulin secretion in vitro and, during acute administration, in vivo Studies in vitro have shown that the stimulation of insulin secretion from pancreatic B-cells by glucose involves the closure of ATP-sensitive K+ channels, leading to depolarization of the cell membrane [4-71. This depolarization is assumed to gate voltage-dependent Ca2+ channels, leading to Ca2+ influx, a prerequisite for insulin release [8-141. The mode of action of SU derivatives has been reported to involve the closure of the same so-called K+(ATP) channels [15-181. If the stimulating effect of SU derivatives on insulin secretion were to involve the same mechanism as glucose (i.e. via K+ channels), the use of these drugs would result in a shift to the left in the dose-response characteristics of glucose-stimulated insulin secretion without a change in the maximum secretion rate. If the stimulating effect were to involve other mechanisms, the dose-response characteristics would presumably show an increase in the maximum secretion rate without a shift to the left. In order to investigate this question, we studied the effect of acute administration of gliclazide on insulin secretion in eight healthy volunteers.
[l-31.
METHODS

Subjects
Eight healthy subjects with a mean age of 22 f 2 years and a weight of 96 f 2.9% of ideal were studied on six different occasions. None of the subjects took any medication.
The study was approved by the local Ethical Committee, and, after the nature of the study had been explained to each subject, informed consent was obtained.
Determination of dose-response characteristics for glucose-stimulated insulin secretion
The subjects were studied in the morning after an overnight fast on six different occasions. They had been instructed to maintain their usual diet.
On each occasion, an intravenous line was inserted in an antecubital vein of each arm and was kept patent by a slow saline [0.9% (w/v) NaCI] infusion. One line was used for blood sampling, and the other for the infusion of glucose. After 90 min, a hyperglycaemic clamp was performed [19] , starting with an intravenous bolus of glucose [20% (w/v); 30 mg/kg per mmol/l intended increase in blood glucose level], followed by a 60 min variable glucose (20%, w/v) infusion aimed at maintaining a blood glucose level of 8, 11 or 32 mmol/l.
Each of these clamps was performed twice, once with and once without administration of gliclazide (80 mg) 90 min before the start of the hyperglycaemic clamp.
Blood sampling
Blood samples for measurement of plasma C-peptide concentration (Novo, Copenhagen, Denmark, modified by using Sac Cell from Wellcome, Dartford, Kent, U.K., as precipitating second antibody) were obtained at the time points -90, -60, -30, 0, 3,4, 5 and 10 min and every 10 min thereafter.
The blood glucose concentration (YSI Glucose Analyzer; YSJ, Yellow Springs, OH, U.S.A.) was measured at -90, -60, -30, 0, 3, 4 and 5 min and subsequently at 2.5 min intervals during the remainder of the experiment.
Calculations
The increments in plasma C-peptide levels at 5 min and at 60 min during the hyperglycaemic clamps were used as an index of first-and second-phase glucoseinduced insulin secretion, respectively.
In order to assess B-cell sensitivity to glucose, increments in plasma C-peptide levels at these time points were fitted to the modified Michaelis-Menten equation of Grodsky (a logistic function) [20] , with a non-linear leastsquares regression computer program [2 11. The equation was:
where C-pep is the measured increment in plasma Cpeptide level, Vmm. is the calculated maximal B-cell responsiveness, ED,, is the half-maximally stimulating blood glucose concentration, Gluc is the ambient blood glucose concentration, and N is the exponent added by Grodsky [20] because it improved the fit of the data.
STATISTICS
Data are given as means f SEM. Student's t-test for paired data was used for statistical analysis of the data.
RESULTS
Hyperglycaemic clamps
In these hyperglycaemic clamp experiments, the blood glucose concentration increased to the intended values (8, 11 and 32 mmol/l) within 5 min, and was maintained at mean values of 8.1 f 0.05 and 8.1 f 0.06, 11.1 f 0.8 and ll.lfO.04, and 31.3f0.23 and 31.4k0.17 mmol/l with coefficients of variation of 4.0 f 0.8 and 4.3 f 0.85, 5.1f1.0 and 5.0k0.8 and 4.8-tO.6 and 4.5f0.6%, respectively, during gliclazide and control study days.
Plasma C-peptide levels increased rapidly during the first 5 min from levels of around 0.5 f0.04 nmol/l to levels of 1.39f0.11 and 1.29f0.13 nmol/l during the hyperglycaemic clamp at 8 mmol/l glucose with and without gliclazide, respectively, to levels of 1.53 k 0.16 and 1.5 1 f 0.12 nmol/l during the clamp at 11 mmol/l glucose, and to levels of 1.77-tO.15 and 1.96f0.16 nmol/l during the clamp at 32 mmol/l glucose. This was followed by a slower increase during the remainder of the clamps to levels of 1.62 f 0.18 and 1.56 f 0.16,2.4 f 0.25 and 2.3f0.2, and 5.4f0.6 and 5.6f0.6 nmol/l for clamps at 8, 11 and 32 mmol/l glucose with and without gliclazide, respectively (Fig. 1) .
Dose-response characteristics for glucose-induced insulin secretion
First-and second-phase insulin secretion increased in a dose-dependent manner (Figs. 2 and 3) . The V,,,,, of firstphase insulin secretion, assessed from the increments in the plasma C-peptide level, was significantly lower than the VmaY, of second-phase insulin release ( P < 0.02). The V,,, of first-phase insulin release showed a trend towards a decrease on the gliclazide study day ( P = 0.10), whereas no significant change in V,,,, was seen for second-phase insulin release ( P > 0.2).
The ED,, was significantly decreased on the gliclazide study days for first-phase insulin release (7.56 f 0.27 versus 9.14f 0.12 mmol/l, P<0.05), whereas no difference was observed for second-phase release. The exponent N was not significantly different between gliclazide and control study days, neither for first-nor second-phase insulin release (Table 1) .
DISCUSSION
The SU derivative gliclazide stimulates insulin secretion in vitro and in vivo [2-41. The present studies were undertaken to examine the influence of acute administration of gliclazide on B-cell glucose sensitivity in both phases of insulin release in healthy subjects. Both phases were studied in order to assess whether this SU derivative may have different effects in these phases. We used plasma C-peptide levels instead of plasma insulin levels as an assessment of insulin secretion, since insulin is known to have non-linear pharmacokinetics (with a non-linear clearance) [22-271. Previous studies from our laboratory indicated a difference in dose-response characteristics for glucoseinduced insulin release when assessed using plasma C-peptide levels or plasma insulin levels, with a significantly higher ED,, for the assessment using plasma insulin levels [28] .
The ED,, values of 9.1 and 12.3 mmol/l obtained in the present study on the control day agree with our previous studies in that the ED,, for first-phase secretion is somewhat lower than the ED,, for second-phase secretion. These values of ED,, are comparable with the ED,, of around 10 mmol/l which has been found in a study in v i m [29] . Since glucose stimulation of insulin secretion involves glucose metabolism [30-331, it has been postulated that the degrading enzyme that has dose-response characteristics comparable with overall degradation (pace-setting enzyme) acts as the glucose 'sensor' of the B-cell [33] . It is now assumed that glucokinase fulfils this role [29, 33] .
In the present study, we assessed the influence of oral administration of the SU derivative, gliclazide, on glucose-induced insulin release in healthy men at moderately elevated and at high glucose levels. During the hyperglycaemic clamps at 8 mmol/l glucose, gliclazide induced 15% higher increases in the plasma C-peptide level for first-phase insulin secretion than on the control study day, whereas no differences were found for the 
Second-phase insulin release
clamps at the higher glucose levels. This 15% augmentation in insulin release at this blood glucose level should not be taken as insignificant, since insulin release (as any process governed by Michaelis-Menten kinetics) is most sensitive to changes in blood glucose level around the ED,, (or K,,,) , which is about 8 mmol/l [28, 29, [32] [33] [34] . Moreover, since many subjects with NIDDM have (fasting) blood glucose levels of around 8 mmol/l, a drug that has a significant effect at this blood glucose level may have considerable value for the management of this disorder.
No difference was noted for the second-phase insulin release. This indicates that the effects of the SU derivative, gliclazide, on insulin secretion is not simply additive to the effects of hyperglycaemia. This influence of gliclazide is also apparent from the change in ED,, for the first-phase glucose-induced insulin release. However, this should not be taken as indicative for an effect of gliclazide on glucokinase. Rather, the decrease in ED,, seems to indicate that gliclazide induces insulin release in man by a mechanism similar, at least in part, to that of glucose.
Since it was recently observed that SU derivatives can also induce closure of these same K+ (ATP) channels, it may be that SU derivatives could have (part of) the mechanism by which they induce insulin release in common with glucose [16-181. Previous studies in man have also shown that SU derivatives can enhance insulin secretion, both at the fasting plasma glucose levels, as during hyperglycaemic clamps, and at moderately elevated blood glucose levels. In previous studies in which four healthy volunteers underwent an intravenous glucose tolerance test, Chiasson et al. [24] also found a significant increase in first-phase insulin release after gliclazide administration. However, since blood glucose levels are not carefully kept at specified levels during an intravenous glucose tolerance test, these studies provide no further insight as to the mechanism of the increase in insulin release. In order to gain a more precise assessment of the effect of SU derivatives on insulin release hyperglycaemic glucose clamps need to be performed, since this enables assessment at (various) precisely defined glucose levels.
In the present study, two moderately elevated levels (8 and 11 mmol/l) and one high level (32 mmol/l) of blood glucose were chosen, since the two first-named are around the presumed ED,, of insulin release and the lastnamed is around the maximum release [28, 30, concluded from studies in healthy volunteers, in whom hyperglycaemic clamps were performed at blood glucose levels of 16 mmol/l, that the effects of acute administration of SU derivatives (glibenclamide and glipizide) and hyperglycaemia on insulin secretion are additive. This same conclusion would appear from studies of Hosker et al. [37] , who investigated the influence of gliclazide at blood glucose levels of 7.5, 10 and 15 mmol/l, after 6 weeks of gliclazide treatment in patients with NIDDM. However, this conclusion can only be drawn when maximally stimulating glucose levels have been attained, which was not the case in either of these studies, since previous studies indicate that maximum insulin release is achieved at blood glucose levels of > 30 mmol/l [28, 38] .
In the present study, we have obtained evidence that although gliclazide enhances first-phase glucose-induced insulin release at a moderately elevated glucose level, its effect on glucose-induced insulin release is not additive at a (nearly) maximally stimulating glucose level. This study therefore indicates that the effects of gliclazide and hyperglycaemia are not simply additive. On the contrary, the finding of an apparently decreased ED,, implies that the promotion by gliclazide and hyperglycaemia of first-phase insulin release involves, at least in part, the same mechanism. This is in agreement with studies in vitro indicating that both SU derivatives and glucose induce closure of K+ (ATP) channels in the B-cell. Interestingly, it appears from the present study that gliclazide does not change the ED,, of second-phase glucose-induced insulin secretion. It is not clear whether this discrepancy is due to an intrinsic inability of gliclazide to influence second-phase insulin release, or whether the time interval between the administration of the gliclazide and the occurrence of the second-phase insulin secretion in the present study was too long to induce an appreciable enhancement of insulin release. The latter, however, does not seem to be likely; in pharmacokinetic studies, Campbell et al. [39] have shown that in man a peak plasma concentration of gliclazide (2-4 pg/ml) is reached some 4 h after a orally administered dose of 80 mg [38] . Moreover, it appeared that the elimination half-life of gliclazide in males is about 8 h. 
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